Related Experiment Video
Updated: Jul 7, 2025
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Patients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate
Chin-Wen Hsu1, Wan-Wen Yang2, Chia-Yi Hou2
1Department of Family Medicine, Chi-Mei Medical Center, Liouying, Tainan 736402, Taiwan.
Insights
Hepatitis C (HCV) patients on direct-acting antiviral (DAA) treatment had lower SARS-CoV-2 infection and mortality rates. Specific DAA medications like Epclusa and Maviret offered superior protection against COVID-19.
Area of Science:
- Virology
- Hepatology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection affects millions globally.
- The COVID-19 pandemic, caused by SARS-CoV-2, poses risks, especially to individuals with chronic conditions.
- Understanding the interaction between HCV, its treatment, and SARS-CoV-2 is crucial for patient management.
Purpose of the Study:
- To investigate the association between direct-acting antiviral (DAA) treatment for HCV and SARS-CoV-2 infection.
- To evaluate the impact of DAA treatment on the severity and mortality of COVID-19 in HCV patients.
- To compare the protective effects of different DAA regimens against SARS-CoV-2.
Main Methods:
- Retrospective analysis of medical records from 602 HCV patients with initial positive nucleic acid tests.
- Comparison of SARS-CoV-2 infection and mortality rates between patients undergoing DAA treatment and those not.
- Assessment of COVID-19 severity and outcomes in patients during and after DAA therapy.
Main Results:
- 9.8% of HCV patients were co-infected with SARS-CoV-2.
- DAA treatment was associated with significantly lower SARS-CoV-2 infection and mortality rates.
- Epclusa and Maviret demonstrated superior protection against SARS-CoV-2.
- HCV patients on DAA treatment experiencing COVID-19 had mild symptoms and no reported deaths.
Conclusions:
- Direct-acting antiviral treatment for Hepatitis C may offer a protective effect against SARS-CoV-2 infection and severe COVID-19 outcomes.
- Specific DAA regimens, including Epclusa and Maviret, show enhanced protection.
- Continued monitoring and healthcare strategies are essential for vulnerable populations during the pandemic.
Abstract:
This study retrospectively analyzed the medical records of 602 patients with first-time positive results for the HCV nucleic acid test between 1 May 2021 and 31 March 2023, exploring the association between DAA treatment and SARS-CoV-2 infection. The results showed that 9.8% of HCV patients were co-infected with SARS-CoV-2. Gender, age, vaccination status, and HCV genotype did not significantly affect SARS-CoV-2 infection. However, patients undergoing DAA treatment showed significantly lower rates of SARS-CoV-2 infection and mortality compared to those not undergoing DAA treatment. The analysis also compared patients undergoing different DAA treatments, with Epclusa and Maviret showing superior protection against SARS-CoV-2. Furthermore, this study explored the severity and mortality of SARS-CoV-2 infection in patients undergoing and having completed DAA treatment. It revealed that patients diagnosed with COVID-19 during DAA treatment experienced only mild symptoms, and none died, suggesting a potential protective effect of DAA treatment against severe outcomes of SARS-CoV-2 infection. The findings contribute to the understanding of the interplay between HCV, DAA treatment, and SARS-CoV-2 infection, highlighting the need for continued monitoring and healthcare measures for individuals with chronic conditions during the ongoing COVID-19 pandemic.
